Background
==========

Stroke is the leading cause of disability and mortality worldwide, resulting in an enormous socioeconomic burden. There has been a greater that 100% increase in stroke incidence rates in low-to-middle income countries over the past 4 decades \[[@b1-medscimonit-23-4415]\]. Readmissions were reported to be 31--53% in the first year after stroke, frequently from recurrent stroke or cardiovascular diseases \[[@b2-medscimonit-23-4415]--[@b4-medscimonit-23-4415]\]. About half of the patients experienced readmission or death during the first year after stroke and carried substantial risk and burden \[[@b5-medscimonit-23-4415]\]. The ability to accurately estimate the 1-year clinical outcome of stroke is very important and may help healthcare providers and family make decisions on a treatment plan, discharge arrangement, and resource use. The risk assessment would aid practitioners in identifying high-risk patients and developing a targeted and cost-effective preventive strategy.

In 2013, the American College of Cardiology/American Heart Association (ACC/AHA) task force developed the Guideline on the Assessment of Cardiovascular Risk and introduced the pooled cohort risk (PCR) equations, which were designed to predict 10-year risk for a first atherosclerotic cardiovascular disease (ASCVD) event \[[@b6-medscimonit-23-4415]\]. The ASCVD event includes non-fatal myocardial infarction (MI), coronary heart disease (CHD) death, as well as non-fatal and fatal stroke. The PCR equations were derived from 4 major population-based cohort studies in the United States involving white and black Americans. The inclusion of stroke as an endpoint is a major strength. It is recommended as a guide to make decision on initiating statin therapy for primary prevention in adults without clinical ASCVD. When the PCR score is ≥7.5%, statin use is recommended for non-diabetic patients. The PCR equations have been further validated by different external cohorts \[[@b7-medscimonit-23-4415],[@b8-medscimonit-23-4415]\].

The present study aimed to validate the performance of the PCR equations in acute ischemic stroke (AIS) and transient ischemic attack (TIA) patients in China. We investigated whether the PCR equations can predict the clinical outcomes, including stroke recurrence, CHD, and vascular death, during 1-year follow-up. We also compared the predictive validity between the PCR equations and the ESSEN score, which has been widely validated internally and externally \[[@b9-medscimonit-23-4415]--[@b11-medscimonit-23-4415]\].

Material and Methods
====================

The cohort was derived from the China National Stroke Registry (CNSR) \[[@b12-medscimonit-23-4415]\], which is the largest, nationwide, multicenter, and prospective registry of consecutive patients with acute cerebrovascular diseases corresponding to World Health Organization diagnostic standards \[[@b13-medscimonit-23-4415]\]. The study of CNSR was approved by the Central Institutional Review Board at Beijing Tiantan Hospital. All patients or their designated relatives signed the informed consent forms and their data were kept confidential and protected. The cohort, comprising AIS and TIA patients, was followed up for 1 year. The inclusion criteria according to the PCR equations were: age: 40--79 years; total cholesterol: 130--320 mg/L; HDL: 20--100 mg/L; and BP: 90--200 mmHg. Patients diagnosed with hemorrhagic strokes, or missing baseline characteristics, or without follow-up outcomes, or did not meet the PCR standards were excluded. Among the 22 216 acute stroke patients who were hospitalized from 132 participating hospitals in the CNSR, a total of 8287 patients, including 7652 AIS and 635 TIA patients, fulfilled the inclusion criteria, finished the follow-up, and were thus enrolled in the study ([Figure 1](#f1-medscimonit-23-4415){ref-type="fig"}).

For the present study, the following baseline variables were analyzed: (1) demographics (age and gender); (2) stroke risk factors: body mass index (BMI), current smoking, and heavy alcohol consumption (≥2 standard alcohol beverages per day), hypertension, diabetes mellitus, dyslipidemia, heart failure, atrial fibrillation, coronary heart disease, peripheral artery disease, and history of stroke/TIA; (3) admission stroke severity based on the National Institutes of Health Stroke Scale score (NIHSS); and (4) pre-admission medications: antihypertensive treatment, hypoglycemic treatment, statins usage, and antiplatelet treatment.

The primary endpoint was stroke recurrence during 1-year follow-up, referring to a new or worsened neurological deficit (defined as NIHSS worsened ≥4), or readmission due to cerebrovascular diseases including ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage. The secondary endpoints were CHD (including MI, coronary revascularization, and cardiac resuscitation) and all-cause vascular death during 1-year follow-up. Blinded trained interviewers obtained the outcome data by using standardized questionnaires via phone calls.

Statistical analysis
--------------------

Data were summarized as mean values and SD for continuous parameters, or absolute count and percentage for categorical endpoints. Comparisons across the groups were examined using the chi-square test for categorical variables. Student's t-test was used for continuous/score variables. To analyze relationship between the risk factors and the outcomes, univariate and multivariate logistic regression were utilized. To validate the discrimination of the PCR equations and the ESSEN score, the area under the receiver operating curve (AUC) by C statistic was assessed. All tests were 2-tailed, and P\<0.05 was considered statistically significant. Statistical analysis was performed using SAS software version 9.3 (SAS Institute Inc, Cary, NC).

Results
=======

Baseline characteristics of the selected 8287 patients are shown in [Table 1](#t1-medscimonit-23-4415){ref-type="table"}. The clinical features, including demographic characteristics, risk factors, and drug treatments, were compared between the patients with and without recurrences. The cumulative 1-year stroke recurrence was 11.27%. Older patients and patients with smoking, heavy drinking, hypertension, diabetes mellitus, dyslipidemia, heart failure, coronary heart disease, atrial fibrillation, history of stroke/TIA, and high admission NIHSS score were more likely to be recurrent (P\<0.05). On the other hand, patients with lipid-lowering agents, antihypertensive agents, hypoglycemic agents, and antiplatelet agents were less likely to be recurrent (P\<0.05).

[Table 2](#t2-medscimonit-23-4415){ref-type="table"} shows the univariate logistic regression analysis results of the risk factors. Older patients (OR 1.250, 95% CI: 1.130--1382), continual smoking (OR 1.296, 95% CI: 1.112--1.510), heart failure (OR 1.947, 95% CI: 1.215--3.119), coronary heart disease (OR 2.004, 95% CI: 1.689--2.378), hypertension (OR 1.514, 95% CI: 1.303--1.759), diabetes mellitus (OR 1.193, 95% CI: 1.018--1.400), dyslipidemia (OR 1.404, 95% CI: 1.162--1.696), history of stroke/TIA (OR 2.046, 95% CI: 1.782--2.350), and high admission NIHSS score (OR 1.017, 95% CI: 1.006--1.028), were associated with higher risk of stroke recurrence. The multivariate logistic regression analysis ([Table 3](#t3-medscimonit-23-4415){ref-type="table"}) found that stoke recurrence was higher in patients with atrial fibrillation and history of stroke/TIA. The adjusted odds ratio was 1.958 (95% CI: 1.508--2.542) and 1.736 (95% CI: 1.496--2.014), respectively.

At 1-year follow-up, the C statistic values were as follows: (1) For the stroke recurrence rate, 0.584 for PCR equations and 0.565 for ESSEN score in AIS patients and 0.573 for PCR equations and 0.558 for ESSEN score in all patients. (2) For non-fatal MI, 0.533 for PCR equations and 0.512 for ESSEN score in AIS patients and 0.493 for PCR equations and 0.520 for ESSEN score in all patients. (3) For vascular death, 0.592 for PCR equations and 0.612 for ESSEN score in AIS patients and 0.592 for PCR equations and 0.609 for ESSEN score in all patients. (4) For all events, 0.582 for PCR equations and 0.579 for ESSEN score in AIS patients and 0.575 for PCR equations and 0.572 for ESSEN score in all patients ([Table 4](#t4-medscimonit-23-4415){ref-type="table"}).

The study subjects were categorized into 2 groups: a low-PCR group (PCR\<20%) and a high-PCR group (PCR ≥20%). For AIS patients, the 12-month cumulative rates of recurrent stroke, vascular death, and combined vascular events were higher in the high-PCR group (P\<0.001); however, the rates for non-fatal MI did not differ between the 2 groups ([Table 5](#t5-medscimonit-23-4415){ref-type="table"}). For TIA patients, there were no significant differences in the 12-month cumulative rates for recurrent stroke, non-fatal MI, vascular death, and combined vascular events between the 2 groups ([Table 6](#t6-medscimonit-23-4415){ref-type="table"}).

Discussion
==========

The present study was primarily conducted to determine whether the PCR equations could predict the 1-year clinical outcome in AIS/TIA patients in China. A previous study showed that the ESSEN score can predict and stratify the risk of recurrent stroke and combined vascular events in Chinese AIS/TIA patients \[[@b14-medscimonit-23-4415]\]. The present results showed that the PCR equations and the ESSEN score had similar predictive validity for either recurrent stroke or cumulative vascular events. In our study results, the C statistic values were approximately 0.6, indicating a moderate predictive value of the 2 scores in stroke/TIA patients in China. We also found that the AUC values of the PCR equations were analogous to those of a recent study wherein the patients were included from the Vitamin Intervention for Stroke Prevention (VISP) trial \[[@b15-medscimonit-23-4415]\]. In the VISP cohort, comprising 3680 patients with an average of 20 months of follow-up, the C statistics of the PCR were 0.56 for stroke and 0.62 for major vascular events.

In the REGARDS study \[[@b7-medscimonit-23-4415]\], the PCR model yielded better discrimination, with the C value 0.72 (95% CI, 0.70--0.75). Although the participants have not been followed up for 10 years, Muntner et al. modified the PCR model into 5-year risk version and the participants were not taking statins at baseline, for which the PCR model was specifically designed to be used. In our study, the PCR model was modified to 1-year and 46.2% had vascular comorbidities, including known-ASCVD and heart failure. Furthermore, in our cohort, there was 2.7% lipid modifier use and the secondary preventions included antithrombotic medication (16.4%), antihypertensive medication (46.9%), and hypoglycemic medication (23.9%). All these may have attenuated the discrimination power of vascular outcome events. Another potential factor was racial difference.

We used 20% as the threshold value to discriminate low and high risk, since a score of ≥20% in 10 years is known to predict increased CVD risk that requires the modification of driving risk factors \[[@b16-medscimonit-23-4415]\]. Our study confirmed that the AIS patients with PCR score ≥20% faced a higher risk of recurrent stroke and combined vascular events, which could not be applied to TIA patients. Other studies also found that high PCR (PCR score ≥20%) predicts a 1.8-fold increase in risk of stroke and a 2.1-fold increase in risk of stroke/CHD/vascular death over a 2-year period \[[@b15-medscimonit-23-4415]\]. The PCR equations may be a potentially useful and easy-to-use risk stratification tool to aid clinicians in identifying patients at high risk of recurrent stroke and vascular events, thereby raising awareness of secondary prevention.

The strengths of this study are the prospective and multicenter design of the CNSR and the large sample size of consecutive stroke patients. Nevertheless, our study also has several limitations. First, selection bias cannot be excluded. All the participating hospitals involved in the CNSR were located in the urban regions because of the selection for intensive care and follow-up, although they represent nationwide areas. The urban areas have more resources and expertise than their rural counterparts. Thus, we might have underestimated the unfavorable events rate. Moreover, our study selected the hospitalized patients, and exclusion of non-hospitalized patients in a study of survival after stroke may introduce significant bias \[[@b17-medscimonit-23-4415]\]. Second, our study did not classify the subtypes of acute ischemic stroke, which might influence the functional outcome, survival, and recurrence of patients \[[@b18-medscimonit-23-4415],[@b19-medscimonit-23-4415]\]. Third, the PCR equations do not involve severity of stroke and information on imaging or laboratory studies, which may affect the outcomes of patients \[[@b20-medscimonit-23-4415]\].

The present report provides the first external validation of the PCR equations in China. In Chinese patients with AIS or TIA, the PCR equations may be a potentially useful tool for predicting the risk of recurrent stroke and combined vascular events.

Conclusions
===========

The current study shows that the PCR equations and the ESSEN score have similar predictive validity for either recurrent stroke or cumulative vascular events. Our study confirms that AIS patients with PCR score ≥20% face a high risk of recurrent stroke and combined vascular events.

The pooled cohort risk equations may serve as potential tools to predict and stratify the 1-year risk of recurrent stroke and combined vascular events in AIS/TIA patients in China. The PCR equations may be a useful and easy-to-use risk tool which can raise awareness of secondary prevention.
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###### 

Baseline characteristics of patients with and without recurrence.

  Characteristics                 Overall                With recurrence        Without recurrence    P-value
  ------------------------------- ---------------------- ---------------------- --------------------- ---------
  Sample size                     8287                   934                    7353                  
  Sex (male), n,%                                                                                     
  Female                          3054/8287 (36.9%)      349 (37.4%)            2705 (36.8%)          
  Male                            5233/8287 (63.1%)      585/934 (62.6%)        4648/7353 (63.2%)     0.7299
  Age, y (mean±SD)                63.24±9.65             64.86±9.05             63.03±9.71            0
  Age, median (Q1--3), y          64 (56--72)            66 (58--73)            64 (55--71)           0
  BMI (kg/m^2^) (mean ±SD)        24.62±3.83             24.68±3.38             24.61±3.88            0.6594
  BMI (kg/m^2^) median (Q1--Q3)   24.34 (22.49--26.45)   24.46 (22.49--26.67)   24.3 (22.48--26.42)   0.1786
   BMI \<25                       4442/7534 (59%)        483/838 (57.6%)        3959/6696 (59.1%)     0.5463
   BMI 25--30                     2698/7534 (35.8%)      314/838 (37.5%)        2384/6696 (35.6%)     
   BMI ≥30                        394/7534 (5.2%)        41 (4.9%)              353 (5.3%)            
  Vascular risk factor, n,%                                                                           
  Smoking                         5664/8287 (68.3%)      683/934 (73.1%)        4981/7353 (67.7%)     0.0009
  Heavy drinking                  2395/8287 (28.9%)      237/934 (25.4%)        2158/7353 (29.3%)     0.0116
  Hypertension                    5285/8287 (63.8%)      671/934 (71.8%)        4614/7353 (62.7%)     0
  Diabetes mellitus               1794/8287 (21.6%)      228/934 (24.4%)        1566/7353 (21.3%)     0.0295
  Dyslipidemia                    1018/8287 (12.3%)      148/934 (15.8%)        870/7353 (11.8%)      0.0004
  Heart failure                   112/8287 (1.4%)        22/934 (2.4%)          90/7353 (1.2%)        0.0048
  Coronary heart disease          1086/8287 (13.1%)      201/934 (21.5%)        885/7353 (12.0%)      0
  Peripheral artery disease       40/8287 (0.5%)         4/934 (0.4%)           36/7353 (0.5%)        0.7989
  Atrial fibrillation             434/8287 (5.2%)        97/934 (10.4%)         337/7353 (4.6%)       0
  History of stroke/TIA           2586/8287 (31.2%)      429/934 (45.9%)        2157/7353 (29.3%)     0
  Admission NIHSS score           5.53+5.93 (8287)       6.09+6.69 (934)        5.46+5.83 (7353)      0.0021
  NIHSS, median (Q1--Q3)          4 (2--8) (8287)        4 (1--8) (934)         4 (2--7) (7353)       0.247
  Drugs                                                                                               
  Lipid-lowering agents           223/8218 (2.7%)        44/919 (4.8%)          179/7299 (2.5%)       0
  Antihypertensive agents         3887/8287 (46.9%)      507/934 (54.3%)        3380/7353 (46.0%)     0
  Hypoglycemic agents             1983/8287 (23.9%)      269/934 (28.8%)        1714/7353 (23.3%)     0.0002
  Antiplatelet agents             1359/8287 (16.4%)      223/934 (23.9%)        1136/7353 (15.4%)     0

BMI -- body mass index; NIHSS -- the National Institutes of Health Stroke Scale. Heavy drinking indicates ≥2 standard alcohol intake/day.

###### 

Risk factors for stroke recurrence by univariate logistic regression.

  Risk factors                OR (95% CI)            P-value
  --------------------------- ---------------------- ---------
  Age                         1.020 (1.013--1.028)   \<0.001
  Age_c                       1.250 (1.130--1.382)   \<0.001
  Gender                      1.025 (0.891--1.180)   0.729
  BMI                         1.004 (0.986--1.023)   0.659
  BMI-cat                     1.032 (0.915--1.164)   0.608
  Smoking                     1.296 (1.112--1.510)   \<0.001
  Heavy drinking              0.819 (0.701--0.956)   0.011
  Heart failure               1.947 (1.215--3.119)   0.005
  Coronary heart disease      2.004 (1.689--2.378)   \<0.001
  Hypertension                1.514 (1.303--1.759)   \<0.001
  Diabetes mellitus           1.193 (1.018--1.400)   0.029
  Dyslipidemia                1.404 (1.162--1.696)   \<0.001
  Peripheral artery disease   0.874 (0.310--2.462)   0.799
  History of stroke/TIA       2.046 (1.782--2.350)   \<0.001
  Admission NIHSS score       1.017 (1.006--1.028)   0.002
  Hypoglycemic agents         1.331 (1.144--1.549)   \<0.001
  Lipid-lowering agents       2.000 (1.428--2.802)   \<0.001
  Antihypertensive agents     1.396 (1.217--1.600)   \<0.001
  Antiplatelet agents         1.716 (1.458--2.021)   \<0.001

OR -- odds ratio; CI -- confidence interval; BMI -- body mass index; NIHSS -- the National Institutes of Health Stroke Scale. Heavy drinking indicates the standard alcohol intake per day ≥2; OR represents the standard alcohol intake per day ≥2 *vs.* \<2.

###### 

Risk factors for stroke recurrence by multivariate logistic regression.

  Risk factors              OR (95% CI)
  ------------------------- ----------------------
  Age                       1.010 (1.002--1.018)
  Admission NIHSS score     1.009 (0.997--1.020)
  Gender                    0.889 (0.746--1.060)
  Smoking                   0.960 (0.803--1.148)
  Heavy drinking            0.925 (0.769--1.114)
  Heart failure             1.026 (0.620--1.698)
  Coronary heart disease    1.515 (1.258--1.826)
  Hypertension              1.367 (1.107--1.689)
  Diabetes mellitus         0.820 (0.659--1.021)
  Dyslipidemia              1.060 (0.857--1.311)
  Atrial fibrillation       1.958 (1.508--2.542)
  History of stroke/TIA     1.736 (1.496--2.014)
  Hypoglycemic agents       1.397 (1.135--1.720)
  Lipid-lowering agents     1.351 (0.929--1.966)
  Antihypertensive agents   0.923 (0.759--1.123)
  Antiplatelet agents       1.159 (0.966--1.390)

OR -- odds ratio; CI -- confidence interval; NIHSS -- the National Institutes of Health Stroke Scale. Reference for age was \<65-years-old. Reference for NI-HSS score was 3. Reference for female sex was male sex. Adjusted for gender, ethnicity, educational background, smoking, heavy drinking, adiposity, and history of disease including heart failure, hypertension, diabetes mellitus, hyperlipidemia, vascular disease, and drug intervention such as antihypertensive agents use, hypoglycemic agents use, lipid-lowering agents use, antiplatelet agents and anticoagulants use.

###### 

Predictive accuracy of PCR equations and ESSEN Score.

                          Recurrence stroke   Non-fatal MI            Vascular death   RS+MI+VD                                                         
  ----------------------- ------------------- ----------------------- ---------------- ------------------------ ------- ----------------------- ------- ----------------------
  PCR                                                                                                                                                   
   AIS                    0.584               4.927 (83.302, 7.353)   0.533            0.825 (0.164, 4.138)     0.592   4.927 (3.221, 7.537)    0.582   4.725 (3.422, 6.525)
   TIA                    0.499               0.753 (0.206, 2.754)    0.490            0.776 (0.004, 140.407)   0.588   9.654 (1.023, 91.116)   0.499   0.872 (0.267, 2.856)
   AIS and TIA patients   0.573               3.945 (2.697, 5.771)    0.493            0.811 (0.174, 3.776)     0.592   5.375 (3.547, 8.145)    0.575   4.174 (3.062, 5.690)
  ESSEN                                                                                                                                                 
   AIS                    0.565               1.095 (1.065, 1.125)    0.512            0.978 (0.881, 1.085)     0.612   1.173 (1.138, 1.210)    0.579   1.117 (1.093, 1.142)
   TIA                    0.495               0.998 (0.922, 1.080)    0.594            0.862 (0.605, 1.227)     0.526   1.028 (0.871, 1.213)    0.503   0.988 (0.918, 1.063)
   AIS and TIA patients   0.558               1.083 (1.055, 1.112)    0.520            0.967 (0.875, 1.068)     0.609   1.169 (1.134, 1.204)    0.572   1.106 (1.083, 1.129)

###### 

12-month cumulative rates for recurrent stroke and combined vascular events stratified by PCR in AIS patients.

              Recurrence stroke   Non-fatal MI   Vascular death   RS+MI+VD                                                             
  ----------- ------------------- -------------- ---------------- ---------- ------- -------- ----- -------- --------- ------ -------- ---------
  PCR \<20%   259                 8.38%                           19         0.59%            218   6.83%              471    14.75%   
  PCR ≥20%    564                 12.72%                          35         0.76%            478   10.37%             961    20.85%   
  Total       823                 10.94%         \<0.001          54         0.69%   0.3891   696   8.92%    \<0.001   1432   18.35%   \<0.001

###### 

12-month cumulative rates for recurrent stroke and combined vascular events stratified by PCR in TIA patients.

              Recurrence stroke   Non-fatal MI   Vascular death   RS+MI+VD                                                         
  ----------- ------------------- -------------- ---------------- ---------- ------- -------- ---- ------- -------- ----- -------- --------
  PCR \<20%   62                  15.82%                          3          0.74%            10   2.48%            74    18.36%   
  PCR ≥20%    49                  13.17%                          3          0.79%            12   3.16%            60    15.79%   
  Total       111                 14.53%         0.2999           6          0.77%   0.9424   22   2.81%   0.5670   134   17.11%   0.3394
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